Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
CN¥ 76.56
Key Takeaways
Risk factor
Good trading liquidity
Data is available to registered users only
Data is available to registered users only
Profitability factor
Greatly overvalued vs peers
Data is available to registered users only
Data is available to registered users only
About
Suzhou Zelgen Biopharmaceuticals Co., Ltd. researches and develops, manufactures, and sells medicines in the People's Republic of China. It offers small molecule and recombinant protein drugs for the treatment of liver cancer, non-small cell lung cancer, colorectal cancer, thyroid cancer, nasopharyngeal carcinomas, myelofibrosis, hemorrhage, and hepatobiliary diseases. The company was founded in 2009 and is...
Company Valuation
Based on key historical and expected multiples, the stock is greatly overvalued relative to its peers. In particular, the stock is overpriced on P/E.
Data is available to registered users only
Buy
Sell